Exploring Nuances Among Targeted and Immune Checkpoint Therapies in Melanoma:
Focus on Mechanisms, BRAF Mutation, and Achieving a Durable Response
Release Date: 02/3/2020
Last Reviewed: 7/30/2020
Expiration Date: 02/3/2021
Time to Complete Activity: 1.0 hour
*This activity expired for credit on February 3, 2021 and is no longer available for credit
Faculty Presenter
Sanjiv S. Agarwala, MD
Professor of Medicine
Temple University School of Medicine
Philadelphia, PA
Steering Committee
Sanjiv S. Agarwala, MD
Professor of Medicine
Temple University School of Medicine
Philadelphia, PA
Ragini R. Kudchadkar, MD
Associate Professor
Department of Hematology and Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, GA
This activity is provided by Paradigm Medical Communications, LLC.
Target Audience
This activity has been designed to address the educational needs of community medical oncologists. It will also be of benefit to surgical oncologists, oncology nurses, residents, fellows, nurse practitioners (NPs), PAs, dermatologists, dermatopathologists, and other clinicians who treat patients with melanoma.
Statement of Need
The treatment of advanced melanoma has shifted dramatically since the introduction of immune checkpoint inhibitors and BRAF/MEK inhibitors. Now, community oncology clinicians have multiple treatment options for their patients with stage III and IV disease that include both targeted and immunotherapies. However, treatment selection is highly complex, requiring consideration of multiple patient-, disease-, and treatment-related variables. It is therefore critical to provide community oncology clinicians with education about optimal treatment selection for immune checkpoint inhibitors with a discussion of how their mechanisms of action (MOA) differ from that of targeted therapies; the latest clinical trial data that provide clues to nuances between and within drug classes; selecting agents that can provide a durable response; sequencing of agents; and differences in safety profiles. Importantly, community oncology clinicians must also be adept at recognizing and effectively managing immune-related adverse events (irAEs).
Learning Objectives
- Review the MOA of immune checkpoint inhibitors and how they differ from those of BRAF–targeted therapies used for the treatment of advanced melanoma
- Select optimal immunotherapy for patients with advanced melanoma, based on the latest clinical trial data, demonstrating durable response rates as well as nuanced differences between immune checkpoint inhibitors and BRAF-targeted therapies
- Effectively manage irAEs associated with immune checkpoint inhibitors used in the treatment of advanced melanoma, according to the latest guideline-recommended strategies
- The Evolving Landscape of Melanoma Treatment
- Immune Checkpoint Inhibitors for Melanoma: Treatment Selection Using the Latest Clinical Trial Data
- Effective Management of irAEs
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PA Continuing Education
PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Disclosure of Commercial Support
This activity is supported by an educational grant from Bristol-Myers Squibb.
Instructions for Participation
To receive a CME certificate of participation, you should:
- Follow instructions to register or log in with your professional information and complete the preactivity assessment
- View the online activity in its entirety
- Complete and submit the online posttest and evaluation
For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949.
There is no fee required for participation in this activity.
Hardware/Software Requirements
This certified CME activity is designed using HTML5 video. As you navigate the video using the supplied controls, the slides will sync to the speaker.
Supported Browsers:
For Desktops (Windows/Mac)
Microsoft Edge 40 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher
For Tablets (iPad/Android/Surface)
iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher
Technical Support: If you have any technical problems or playback issues email us at contactus@paradigmmc.com.
Disclosures
In accordance with ACCME requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.
Steering Committee
Sanjiv S. Agarwala, MD
Retained Consultant: Bristol-Myers Squibb; Merck & Co., Inc
Ragini R. Kudchadkar, MD
Retained Consultant: Array BioPharma Inc.; Bristol-Myers Squibb; Immunocore; Novartis Pharmaceuticals Corporation
Grant/Research Support: Bristol-Myers Squibb; Merck & Co., Inc
Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.
Independent peer reviewer has no financial relationships to disclose.
Independent fellow has no financial relationships to disclose.
Resolution of Conflict of Interest
Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.
Disclaimer
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As an ACCME-accredited provider, Paradigm Medical Communications, LLC activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.
Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC, accepts no liability for the content referenced in this activity.
Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website"). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.
Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.
Contact Us
If you have any questions or comments, please email us at contactus@paradigmmc.com.
© 2020 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.